The article ” Phase 1 study of opaganib, an oral sphingosine kinase 2-specific inhibitor, in relapsed an/or refractory multiple myeloma” has been published.
Ann Hematol. 2023 Feb;102(2):369-383. doi: 10.1007/s00277-022-05056-7.
The article ” Phase 1 study of opaganib, an oral sphingosine kinase 2-specific inhibitor, in relapsed an/or refractory multiple myeloma” has been published.
Ann Hematol. 2023 Feb;102(2):369-383. doi: 10.1007/s00277-022-05056-7.